A new class of pain-relieving drugs, derived from histamine antagonists, has recently been discovered. The prototype (named improgan) shows the following characteristics after direct injection into the brain: a) highly effective, morphine-like antinociception on thermal and mechanical tests, b) no impairment of motor coordination or locomotor activity, e) mechanism that is independent of known receptors for histamine and opioids, d) lack of tolerance with daily dosing, and e) unique structure-activity relationships among chemical congeners. Several impediments exist in the development of these agents: l) the mechanism of action is unknown, 2) high-potency congeners have not been discovered, 3) many have H2 or H3-blocking side effects (but do not produce analgesia through these receptors), and 4) the compounds do not penetrate the blood brain barrier after systemic dosing. The experiments below in rats and mice will discover new analgesic congeners of improgan with enhanced potency, reduced side effects and improved brain-penetrating properties:
Aim l) Synthesize and test new improgan-like analgesics which lack H2 and H3 receptor side effects, and possess enhanced analgesic potency. Pilot results indicate that open chain; furan-containing congeners will show these properties.
Aim 2) Synthesize and test brain-penetrating improgan-like analgesics. Pilot studies show the feasibility of discovering such compounds.
Aim 3) Determine the in vitro actions of these new drugs on two new radioligand binding assays being developed to predict improgan analgesia.
Aim 4) Study the activity of selected new compounds in vivo: a) classify their analgesic mechanism by treatments with transmitter agonists and antagonists, and b) assess their clinical potential in several different nociceptive tests and after various routes of administration. This project, which is a collaborative effort between medicinal chemists and pharmacologists, will produce new, brain-penetrating, non-opioid analgesics with the efficacy and potency of morphine. These experiments will help to discover the mechanism of action of this novel class of agents, and lead to the development of new pharmacotherapies for pain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA015915-03
Application #
6896773
Study Section
Integrative, Functional and Cognitive Neuroscience 8 (IFCN)
Program Officer
Hillery, Paul
Project Start
2003-07-01
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
3
Fiscal Year
2005
Total Cost
$280,854
Indirect Cost
Name
Albany Medical College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
190592162
City
Albany
State
NY
Country
United States
Zip Code
12208
Cannon, Keri E; Chazot, Paul L; Hann, Victoria et al. (2007) Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain 129:76-92
Gehani, Neal C; Nalwalk, Julia W; Razdan, Raj K et al. (2007) Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain 8:850-60
Hough, L B; Menge, W M P B; van de Stolpe, A C et al. (2007) Antinociceptive activity of furan-containing congeners of improgan and ranitidine. Bioorg Med Chem Lett 17:5715-9
Hough, Lindsay B; Nalwalk, Julia W; Phillips, James G et al. (2007) CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Neuropharmacology 52:1244-55
Salussolia, Catherine L; Nalwalk, Julia W; Hough, Lindsay B (2007) Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. Brain Res 1152:42-8
Cannon, Keri E; Leurs, Rob; Hough, Lindsay B (2007) Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively. Pharmacol Biochem Behav 88:122-9
Hough, Lindsay B; de Esch, Iwan J P; Janssen, Elwin et al. (2006) Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology 51:447-56
Hough, Lindsay B; Nalwalk, Julia W; Lu, Qun et al. (2005) Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic. Eur J Pharmacol 522:38-46